Drug class
Janus kinase 1/2 and activin A receptor type 1 (ACVR1/ALK2) inhibitor; targeted myelofibrosis therapy
Mechanism of action
Inhibits wild-type JAK1 and JAK2 and mutant JAK2 V617F, reducing cytokine-driven JAK-STAT signalling. It also inhibits ACVR1/ALK2, reducing hepcidin expression and increasing iron availability for erythropoiesis, which is relevant to its effect on anaemia.
General use cases
- Treatment of adults with intermediate- or high-risk myelofibrosis, including primary myelofibrosis and secondary myelofibrosis after polycythaemia vera or essential thrombocythaemia, in patients with anaemia
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
